Conv. Plasma
Nigella Sativa

All HCQ studies
Meta analysis
study COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Azvudine Meta Metformin Meta
Bromhexine Meta
Budesonide Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Famotidine Meta Nitazoxanide Meta
Favipiravir Meta Paxlovid Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  

SARS-CoV-2, a virus with many faces: a series of cases with prolonged persistence of COVID-19 symptoms

Sofian et al., Wiener Medizinische Wochenschrift, doi:10.1007/s10354-020-00793-8
Dec 2020  
  Source   PDF   All Studies   Meta AnalysisMeta
Report on a series of 10 patients experiencing prolonged COVID-19 symptoms that were given HCQ 250mg bid for 5 days, with resolution of symptoms in all cases, and patients reporting they felt much better 2 days after treatment initiation.
Sofian et al., 14 Dec 2020, peer-reviewed, 7 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
SARS-CoV‑2, a virus with many faces: a series of cases with prolonged persistence of COVID-19 symptoms
Masoomeh Sofian, Ali Akbar Velayati, Mohammad Banifazl, Fatemeh Fotouhi, PhD Mona Sadat Larijani, Neda Afzali, MD Amitis Ramezani
Wiener Medizinische Wochenschrift, doi:10.1007/s10354-020-00793-8
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as the causative agent of the ongoing pandemic, has spread into more than 200 countries to date. The disease which is caused by the virus is termed COVID-19. In most cases, it presents at first like common flu with cough and other respiratory symptoms. Nevertheless, other symptoms have been reported, such as a feeling of extreme fatigue, gastrointestinal symptoms, or acute onset of olfactory and gustatory dysfunction. Here we report a series of 10 cases (1 male, 9 females) observed between February and April 2020, with an undulating appearance and disappearance of symptoms. Weeks passed before the diagnosis was established. Symptoms resolved rapidly after treatment with hydroxy-
Conflict of interest M. Sofian, A.A. Velayati, M. Banifazl, F. Fotouhi, M.S. Larijani, N. Afzali, and A. Ramezani declare that they have no competing interests. Ethical standards The study design was approved by the Arak University of Medical Sciences Ethical Committee (IR.ARAKMU.REC.1399.002). Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Ahrends, Busselaar, Severson, CD4+ T cell help creates memory CD8+ T cells with innate and help-independent recall capacities, Nat Commun
Catanzaro, Fagiani, Racchi, Corsini, Govoni, ImmuneresponseinCOVID-19: addressingapharmacological challenge by targeting pathways triggered by SARS-CoV-2, Signal Transduct Target Ther
Chan, Kok, Zhu, Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan, Emerg Microbes Infect
Chen, Liu, Liu, Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia, Zhonghua Jie He He Hu Xi Za Zhi
Chen, Zhou, Dong, Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet
Dhama, Sharun, Tiwari, COVID-19, an emerging coronavirusinfection: advancesandprospectsindesigning and developing vaccines, immunotherapeutics, and therapeutics, Hum Vaccin Immunother
Garcíalf, Immuneresponse,inflammation,andtheclinical spectrum of COVID-19, Front Immunol, doi:10.3389/fimmu.2020.01441
Heymann, Data sharing and outbreaks: best practice exemplified, Lancet
Hoffmann, Kleine-Weber, Krüger, Müller, Drosten et al., The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells, bioRxiv, doi:10.1101/2020.01.31.929042
Hopkins, Coronavirus COVID-19 global cases map
Huang, Wang, Li, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Kumar, Poonam, Rathi, Coronavirus disease COVID-19: a new threat to public health, Curr Top Med Chem
Li, Guan, Wu, Early transmission dynamics in Wuhan, China, of novel Coronavirus-infected pneumonia, N Engl J Med
Liao, Liu, Yuan, The landscape of lung bronchoalveolar immune cells in COVID-19 revealed by singlecell RNA sequencing, medRxiv, doi:10.1101/2020.02.23.20026690
Rajgor, Lee, Archuleta, Bagdasarian, Quek, The many estimates of the COVID-19 case fatality rate, Lancet Infect Dis, doi:10.1016/S1473-3099(20)30244-9
Rokni, Ghasemi, Tavakoli, Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: comparison with SARS and MERS, Rev Med Virol, doi:10.1002/rmv.2107
Shi, Wang, Shao, COVID-19 infection: the perspectives on immune responses, Cell Death Differ
Siracusano, Pastori, Lopalco, Humoral immune responses in COVID-19 patients: a window on the state of the art, Front Immunol
Tian, Hu, Niu, Liu, Xu et al., Pulmonary pathology of early-phase 2019 novel Coronavirus (COVID-19) pneumonia in two patients with lung cancer, J Thorac Oncol
Walls, Park, Tortorici, Wall, Mcguire et al., Structure, function, and antigenicity of the SARS-coV-2 spike glycoprotein, Cell
Wang, Hu, Hu, Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus-Infected pneumonia in Wuhan, China, JAMA
Worldmeter, Coronavirus cases
Zhao, Yuan, Wang, Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019, Clin Infect Dis
Zhou, Yang, Wang, A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature
Zhu, Zhang, Wang, A novel Coronavirus from patients with pneumonia in China, 2019, N Engl J Med
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of over 100,000 datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop